Chemistry:5F-CUMYL-PEGACLONE
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H27FN2O |
| Molar mass | 390.502 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB1 receptor. [1][2] It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.[3]
See also
- 5F-CUMYL-PINACA
- CUMYL-5F-P7AICA
References
- ↑ "Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE". Forensic Toxicology 37 (1): 154–163. 2019. doi:10.1007/s11419-018-0447-4. PMID 30636984.
- ↑ "In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration". Drug Testing and Analysis 12 (9): 1336–1343. June 2020. doi:10.1002/dta.2870. PMID 32490586. https://biblio.ugent.be/publication/8687072.
- ↑ "Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE.". Forensic Toxicology 38 (2): 314–326. 2019. doi:10.1007/s11419-019-00514-w.
 |  |
